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Abstract 
Current antibiotics for treating Clostridium difficile infections (CDI), that is, metronidazole, vancomycin 
and more recently fidaxomicin, are mostly effective but treatment failure and disease relapse remain as 
significant clinical problems. The shortcomings of these agents are attributed to their low selectivity for 
C. difficile over normal gut microflora and their ineffectiveness against C. difficile spores. This Letter 
reports that certain diarylacylhydrazones identified during a high-throughput screening/counter-screening 
campaign show selective activity against two Clostridium species (C. difficile and Clostridium 
perfringens) over common gut commensals. Representative examples are shown to possess activity 
similar to vancomycin against clinical C. difficile strains and to kill stationary-phase C. difficile cells, which 
are responsible for spore production. Structure-activity relationships with additional synthesised 
analogues suggested a protonophoric mechanism may play a role in the observed activity/selectivity and 
this was supported by the well-known protonophore carbonyl cyanide m-chlorophenyl hydrazone (CCCP) 
showing selective anti-Clostridium effects and activity similar to diarylacylhydrazones against stationary-
phase C. difficile cells. Two diarylacylhydrazones were shown to be non-toxic towards human FaDu and 
Hep G2 cells indicating that further studies with the class are warranted towards new drugs for CDI. 
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Abstract 
Current antibiotics for treating Clostridium difficile infections (CDI), i.e. metronidazole, vancomycin 
and more recently fidaxomicin, are mostly effective but treatment failure and disease relapse remain as 
significant clinical problems. The shortcomings of these agents are attributed to their low selectivity for 
C. difficile over normal gut microflora and their ineffectiveness against C. difficile spores. This paper 
reports that certain diarylacylhydrazones identified during a high-throughput screening/counter-
screening campaign show selective activity against two Clostridium species (C. difficile and C. 
perfringens) over common gut commensals. Representative examples are shown to possess activity 
similar to vancomycin against clinical C. difficile strains and to kill stationary-phase C. difficile cells, 
which are responsible for spore production. Structure-activity relationships with additional synthesised 
analogues suggested a protonophoric mechanism may play a role in the observed activity/selectivity 
and this was supported by the well-known protonophore carbonyl cyanide m-chlorophenyl hydrazone 
(CCCP) showing selective anti-Clostridium effects and activity similar to diarylacylhydrazones against 
stationary-phase C. difficile cells. Two diarylacylhydrazones were shown to be non-toxic towards 
human FaDu and Hep G2 cells indicating that further studies with the class are warranted towards new 
drugs for CDI. 
 
  Clostridium difficile-associated diarrhoea (CDAD), also known as C. difficile infection (CDI), is 
the leading cause of infectious nosocomial gastrointestinal illness.1,2 Steadily increasing CDI rates in 
US hospitals,1 emergence of epidemic and hypervirulent strains (e.g. BI/NAP1/027),3 increased 
incidences of community acquired CDI4 and enormous costs to healthcare systems (estimated at $3.2 
billion/year in the US alone)5 have focused considerable attention on this disease over the past 
decade.6,7 
C. difficile is a Gram-positive, rod-shaped, spore-forming anaerobe transmitted via the oral-
fecal route. In its vegetative form it is highly sensitive to oxygen but its spores are heat stable, 
insensitive to standard disinfectants, able to survive for long periods in the environment and they can 
passage intact through the acidic stomach. C. difficile typically resides asymptomatically in the human 
gastrointestinal tract until normal microflora are disrupted, such as following broad-spectrum antibiotic 
treatments, after which it can overgrow producing three toxins; toxin A (TcdA), toxin B (TcdB) and the 
binary toxin CDT.. Ensuing CDI can range in severity from mild diarrhoea to life-threatening 
pseudomembranous colitis (PMC) and toxic megacolon.6  
Treatments for CDI historically have involved antibiotic withdrawal followed by oral 
metronidazole 1 (500 mg t.i.d, 10-14 days) or vancomycin 2 (125-250 mg q.i.d, 10 days) but treatment 
failure remains as a significant and increasing problem (reportedly > 35% for metronidazole and 1-16% 
for vancomycin).2 For patients who develop severe CDI (diarrhoea with leucocytosis, PMC or toxic 
shock) metronidazole is effective in 76% of cases and vancomycin 97%.2 Upwards of 20-30% of 
patients can experience recurrent CDI with intermittent episodes arising over months and sometimes 
years.8 A major risk factor for recurrent CDI is failure to re-establish normal protective gut microflora 
due to the action of metronidazole and vancomycin on gut commensals and the ineffectiveness of these 
antibiotics against C. difficile spores.2 
In 2011 the US Food and Drug Administration (FDA) approved fidaxomicin 3 (Dificid®, 
Optimer Pharmaceuticals Inc.),9 an oral macrocyclic narrow-spectrum antibiotic developed specifically 
for CDI. Fidaxomicin shows very high in vitro potency against C. difficile (minimum inhibitory 
concentrations (MICs) against clinical isolates 0.008–0.25 mg/L) and reduced activity against gut 
commensals, in particular Bacteroides species.10 This and lower post-treatment C. difficile spore 
counts10 are thought to contribute to reduced CDI recurrence with fidaxomicin.11,12 Relapse rates for 
infections caused by the BI/NAP1/027 hypervirulent strain, however, are the same for vancomycin and 
fidaxomicin13,14 and many hospitals have been slow to embrace the new drug due to its high cost (> 
US$2700 per treatment, c.f. metronidazole US$22 and vancomycin $1270).15  
 While the proper place for fidaxomicin in clinical practice is still being established the search 
continues for alternative and, ideally, more cost-effective agents. Attractive new compound classes 
would include those that show high selectivity for C. difficile over gut commensals along with activity 
against the stationary-phase cells responsible for spore formation.16 In a recent high-throughput 
screening (HTS) and counter-screening campaign we identified that certain diarylacylhydrazones are 
clostridium-selective agents.17 This paper reports the activity and selectivity of diaryacylhydrazone 
screening hits, describes structure-activity studies around the class and reports that a representative 
member is active against stationary-phase C. difficile cells. Evidence is presented that selective anti-
Clostridium activity in the class may arise, in part, through a protonophoric mechanism. 
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Figure 1. Current antibiotic treatments for C. difficile infections. 
 
  High-throughput screening was carried out to identify hits against C. difficile CD196.17 Hits 
were subjected to a counter-screening panel of ten bacterial species representing the major taxonomic 
groups from the human gut environment in order to identify Clostridium-selective compounds. 
Counter-screening species were chosen from the Data Analysis and Coordination Centre (DACC) for 
the Human Microbiome Project (http://www.hmpdacc.org/), part of the National Institutes of Health 
(NIH) Roadmap for Medical Research, and included abundant members of the gut flora, e.g. 
Bacteroides thetaiotaomicron, organisms of clinical significance, e.g. Escherichia coli, Enterococcus 
faecalis and Staphylococcus aureus, along with representatives from each of the predominant phyla. 
Clostridium perfringens was included to identify species-specific anti-C. difficile compounds. 
Four acylhydrazones carrying aryl substituents at R1 and R2 (i.e. diarylacylhydrazones 4-7, 
Figure 2) were initially identified as hits. Follow-up measurements showed that the minimum 
inhibitory concentrations (MIC) of 4-7 against C. difficile CD196 ranged from 1.56-6.25 g/mL and 
that the compounds exhibited similar MICs against Clostridium perfringens. Minimum bactericidal 
concentrations (MBC) of two examples chosen for further study (i.e. compounds 5 and 6, see below) 
against CD196 were equivalent to their MICs, confirming that the compounds are bactericidal. 
Quinolinium acetate, chloride and mesylate salts of 7 showed identical activity to the free base 7. 
Compound 4 was shown to have activity similar to vancomycin (< 2-fold difference in MIC) against 
five C. difficile clinical isolates (Supporting Information, Figure S1).17 Importantly, compounds 4-7 
were essentially inactive (MIC > 50 g/mL) across the gut commensal panel with only 5 and 6 showing 
weak activity (MIC = 12.5-25 g/mL) against B. fragilis and B. thetaiotaomicron. In contrast, 
metronidazole 1, vancomycin 2 and fidaxomicin 3 all showed high potency against C. difficile 
accompanied by significant activity against commensals (Figure 2). 
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Figure 2. Activity of metronidazole 1, vancomycin 2, fidaxomicin 3 and diarylacylhydrazones 4-7 
against C. difficile CD196 and a panel of gut commensals. 
 
Three structural motifs common in hits 4-7 were: (1) an acyl hydrazone, (2) an aryl ring at R1 
and (3) an aryl ring at R2 carrying an ortho-hydroxy substituent. Follow-up similarity searches of our 
libraries identified six additional diarylacylhydrazones containing the 2-hydroxynaphthalene group at 
R2 available for examination (Supporting Information, Figure S2, compounds S1-S6). Compounds S1-
S3, which incorporate phenyl, m-bromophenyl and o-hydroxynaphthyl groups at R1, respectively, 
displayed MICs against CD196 in the range 6.25-12.5 g/mL. Compounds S4-S6, which carry 4-
nitrophenyl, 3-nitrophenyl and 3,5-dinitrophenyl substituents at R1, respectively, all showed no activity 
against CD196. These findings indicate that substituents on the aryl group at R1 can dramatically 
impact potency. A further nine compounds with structures related to 4-7 but lacking one or more of the 
above criteria (Supporting Information, Figure S3, S7-S15) were selected from the libraries for testing 
and found to be inactive. Diarylacylhydrazones with aryl rings at R1 and ortho-hydroxy substituted aryl 
rings at R2 thus appear to present the minimal structural requirements for selective anti-Clostridium 
activity in the class. 
 Encouraged by these results, analogues 8-19 (Figure 3) were synthesised to answer specific 
structure-activity questions about the class. The targeted compounds were all prepared by heating the 
requisite R1-acylhydrazines (prepared by reacting precursor methyl esters with hydrazine) and R2-aryl 
aldehydes overnight in ethanol (Figure 3). Yields ranging from 70-90% of the pure compounds were 
obtained after silica-gel column chromatography and/or recrystallization. Compound 8 (INP0400) 
carrying a p-chlorophenyl group at R1 and a 2-hydroxynaphthyl group at R2 was targeted because it had 
previously been reported as an inhibitor of type III secretion in the common bacterial pathogen 
Chlamydia trachomatis.18 The MIC of 8 against CD196 was found to be 6.25 g/mL and it showed 
higher potency against C. perfringens (MIC ≤ 0.78 g/mL). The compound’s selectivity for 
Clostridium species over gut commensals was similar to 5 showing only weak activity against B. 
fragilis and B. thetaiotaomicron (MIC = 12.5 g/mL) and no other activity across the panel. 
 Compound 9, which substituted the ortho-hydroxynaphthyl group present at R2 in 5 with the 
ortho-vanillyl moiety of 7, was synthesized to probe the effect of interchanging the two different R2 
groups present in diarylacylhydrazone screening hits. Clostridium-selective activity was observed with 
9 which showed MICs of 12.5 and 6.25 g/mL against C. difficile and C. perfringens, respectively, and 
no other activity across the panel. Replacing the ortho-hydroxynaphthyl group at R2 of 6 with the 
ortho-vanillyl moiety (i.e. compound 10), however, abolished all activity, including against both 
Clostridium species. Total loss of activity across the panel was similarly observed with 11, where the 
ortho-vanillyl group at R2 in 7 was replaced with the ortho-hydroxynaphthyl group. These results 
demonstrate that the Clostridium-selective activity of diarylacylhydrazones is structure-dependent and 
is affected by substituents on both aryl groups at R1 and R2. 
 The importance of the ortho-hydroxy group at R2 was established next with compounds 12-15.  
Transferring the hydroxyl group of 5 to the naphthyl 4-position (compound 12) led to total loss of 
activity, as did removing the ortho-hydroxy group altogether from compounds 5, 6 and 7 (compounds 
13, 14, and 15, respectively). Methylation of the acylhydrazone ‘amide’ nitrogen of 5 (compound 16), 
its ortho-phenolic group at R2 (i.e. compound 17) or both of these groups (compound 18) similarly 
removed all activity. 
 It was noted that diarylacylhydrazones structurally resemble nitrofurans, an older class of broad 
spectrum antibiotics that have seen widespread historical use in humans and in veterinary medicine.19 
Nitrofurans typically contain an acylhydrazone substituted with a 5-nitrofuranyl group at the position 
corresponding to R2 in diarylacylhydrazones. A variety of substituents, both aryl and non-aryl, can be 
present at the position corresponding to R1 (e.g.  R1 = p-hydroxyphenyl, nifuroxazide; R1 = NH2, 
nitrofurazone; R1 = hydantoin, nitrofurantoin; R1 = oxazolidinone, furazolidone). The novel nitrofuran 
19, carrying a 3-methylpyrazole group at R1 and thus high structural similarity to 6, was synthesised to 
explore the possibility that nitrofurans and diarylacylhydrazones might share overlapping antibacterial 
mechanism(s) of action. However, 19 showed broad spectrum activity across the panel, including high 
potency against C. difficile CD196 (MIC = 0.78 g/mL, Figure 3), confirming that 
diarylacylhydrazones and nitrofurans exert their antibacterial effects via different mechanisms. 
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Figure 3. Activity of synthesized diarylacylhydrazones 8-19 against C. difficile CD196 and a panel of 
gut commensals. 
 
Demonstrating that nitrofurans invoke different antibacterial mechanisms and that anti-
Clostridium activity is lost in diarylacylhydrazones upon methylation of the ‘amide’ nitrogen and/or the 
ortho-phenolic group present at R2 led to speculation that the compounds might be exerting their 
selective effects through a protonophoric mechanism. To test this hypothesis, MIC measurements were 
obtained with three well-known membrane-active protonophores; carbonyl cyanide m-
chlorophenylhydrazone (CCCP),20 pentachlorophenol (PCP),21 and 2,4-dinitrophenol (2,4-DNP)22 
(Figure 4) against CD196 and the gut panel. It was reasoned that if Clostridium-selective activity were 
observed with one or more of these it would support a protonophoric mechanism for 
diarylacylhydrazones. CCCP was found to be highly active against CD196 (MIC = 1.56 g/mL) and 
also showed high selectivity, affecting only one other panel member (B. longum, MIC = 3.25 g/mL). 
In contrast to diarylacylhydrazones, CCCP showed no activity against C. perfringens. PCP and 2,4-
DNP showed only weak activity across the panel and no selectivity towards Clostridium, indicating 
that selective action against Clostridium is not a general effect of protonophores. The similarity 
between the activity/selectivity observed with CCCP and diarylacylhydrazones implies that a 
protonophoric mechanism probably plays some role in the mechanism. That CCCP and 
diarylacylhydrazones both carry hydrazone moieties may be important but this remains to be 
determined. 
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Figure 4. Activity of three protonophores against C. difficile CD196 and a panel of gut commensals. 
 
 Recent reports indicate that perturbing membrane function represents a promising strategy 
towards novel anti-C. difficile therapeutics,23 especially since some membrane–active agents affect the 
quiescent/stationary-phase cells responsible for spore formation.24 Two membrane-active agents 
oritavancin (vancomycin analogue)25 and CB-183,315 (daptomycin analogue)26 are in clinical 
development for CDI. Several membrane-active compounds (including CCCP) were recently shown to 
kill C. difficile cells in both logarithmic- and stationary-phase cultures.27 The activity of 
diarylacylhydrazones 5 and 6 was thus examined against stationary-phase C. difficile CD196 cells 
alongside CCCP, with metronidazole 1, vancomycin 2 and fidaxomicin 3 included for comparison. 
CD196 cells were grown to stationary phase according to an in-house procedure (Supporting 
Information) and treated with 1x, 5x, 10x and 20x the previously determined MIC (g/mL) 
concentrations of each compound. Metronidazole 1, vancomycin 2 and fidaxomicin 3 showed little or 
no activity at all concentrations tested (Figure 5a-c). Compound 5 showed some ability to kill 
stationary-phase cells but the data was not reproducible (not shown) and it was suspected that the poor 
solubility of 5 in the assay medium may have been partially responsible. Switching to the more soluble 
6 produced reproducible dose-dependent cell-killing effects that were remarkably similar to those 
observed with CCCP (Figure 5d-e), supporting the postulate that diarylacylhydrazones and CCCP may 
indeed exert their selective anti-Clostridium effects through overlapping (protonophoric) mechanisms. 
 
 
Figure 5. Activity against stationary-phase C. difficile CD196 cells of: (a) metronidazole 1 (b) 
vancomycin 2 (c) fidaxomicin 3 (d) 6 (e) CCCP. DMSO was present at a final concentration of 1% v/v 
in all assay solutions. 
 
 Given the known effects of CCCP as a protonophoric uncoupler of oxidative phosphorylation,28 
it was of interest to examine human cell cytotoxicity as a preliminary indicator of druggability (or 
otherwise) in the diarylacylhydrazone class. Compounds 5 and 6 were examined alongside miconazole 
(positive control), metronidazole 1, vancomycin 2 and CCCP for cytotoxicity against human FaDu and 
Hep G2 cells using a standard 96-well resazurin-based cell viability assay (Supporting Information). 
The positive control miconazole showed the expected cytotoxic concentration (50 g/mL) against both 
cell lines. Metronidazole 1 and vancomycin 2 showed no toxicity at or below 200 g/mL against either 
cell line. Compounds 5 and 6 showed no cytotoxicity against either cell line at 100 g/mLwhile CCCP 
was found to be toxic at 50 g/mL (Figure 6). 
 
Compound
Cytotoxic conc. ( g/mL)
Vancomycin
1
FaDu HepG2
>200 >200
5
6
Miconazole
Metronidazole
50 50
CCCP 50 50
DMSO showed no cytotoxicity at 2% (v/v).
>200 >2002
>100 >100
>100 >100
 
Figure 6. Cytotoxicity against human FaDu and HepG2 cells.  
 
This study demonstrates that certain diarylacylhydrazones are narrow-spectrum antibacterials 
with selectivity for C. difficile and C. perfringens over other gut commensals. The demonstrated 
structure-dependence of the selectivity is significant because other diarylacylhydrazones have 
previously been shown to have a wider spectrum of antibacterial activity.29 The activity of 6 against 
stationary-phase C. difficile cells and its low human cell cytotoxicity indicate that further investigations 
with the class are warranted towards creating cost-effective antibiotics for CDI that may reduce 
treatment failure and relapse rates. Identifying that CCCP shows similar activity to 
diarylacylhydrazones against the gut panel and against stationary phase C. difficile cells suggests that a 
protonophoric mechanism may play a role in the selectivity, although many questions remain. One 
avenue we are exploring is the possible involvement of dynamin-like proteins, which are important 
mediators of membrane remodelling in bacteria (called dynamins in eukaryotes).30 Inhibition of 
dynamins by diarylacylhydrazones is well characterised31 and compounds structurally very similar to 
those reported here were recently shown to prevent uptake of C. difficile TcdA into eukaryotic cells.32 
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